SPECIAL NOTICE
A -- Identification, Characterization and Development of Inhibitors of the p53 Tumor Suppressor Protein
- Notice Date
- 8/8/2003
- Notice Type
- Special Notice
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Bldg 427 Room 12, Frederick, MD, 21702
- ZIP Code
- 21702
- Solicitation Number
- Reference-Number-KH-01
- Point of Contact
- Bonnie Chamberlain, Marketing Coordinator, Phone (301)435-3134, Fax (301)402-2117, - Bonnie Chamberlain, Marketing Coordinator, Phone (301)435-3134, Fax (301)402-2117,
- E-Mail Address
-
chamberbo@mail.nih.gov, chamberbo@mail.nih.gov
- Description
- The tumor suppressor protein, p53, is an important component of the cellular machinery that responds to genotoxic stresses, and acts as an "emergency brake" to maintain genomic integrity by either arresting the cell cycle or by inducing a form of programmed cell death termed apoptosis. The value that p53 activation plays in protecting proliferative cells from passing on genetic instability by inducing apoptotic cell death is counterbalanced by the disadvantage caused by the same machinery in non-proliferative, end-differentiated cells (such as neurons) that cannot be replaced. For example, a large component of the cellular death involved in stroke, brain trauma, Alzheimer's disease, Parkinson's disease, and heart disease involves the activation of a final common cascade of biochemical and cellular events for which p53 is a gatekeeper. In this regard, novel small compounds have been synthesized that potently inhibit the activation of p53 caused by a toxic and usually lethal insult, to thereby protect cells from dying. The NIA seeks a CRADA Collaborator to develop p53 -inhibiting compounds with drug-like characteristics for clinical assessment and to identify and characterize human diseases which would most benefit from transient inactivation of p53. Potential Areas of Application ? Possible therapeutic use of p53 inactivators to inhibit cell death associated with brain trauma, Alzheimer's disease, Parkinson's disease, and heart disease. Main Advantages of Technology/Invention ? The inhibitors preserve dopaminergic neurons and motor function in experimental Parkinsonism. Current State of Development ? Several p53-inhibiting compounds have been synthesized and shown to inhibit apoptosis. Further R&D Required ? Pre-clinical and clinical development ? Develop a strategy to determine for which human diseases transient inactivation of p53 is most beneficial. Patent Status ? U.S. Patent Application filed October 18, 2000. Pertinent References ? Culmsee C, et. al. J.Neurochem. 2001, 77:220-228. ? Zhu X, et. al. Med. Chem. 2002, 45: 5090-5097. ? Duan W, et. al. Annals Neurol. 2002, 52:597-606. Contact Information ? CRADA contact: Kathy Higinbotham, Technology Transfer Branch, NCI Phone: 301-496-0477; E-mail: higinbok@mail.nih.gov ? Licensing contact: Norbert Pontzer, Ph.D., J.D., Office of Technology Transfer, NIH, Phone: 301-496-7736; E-mail: pontzem@od.nih.gov
- Record
- SN00395984-W 20030810/030808213410 (fbodaily.com)
- Source
-
FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |